Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics, Inc. (JANX)
:JANX
JANX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.97 - $71.71
Previous CloseN/A
Volume1.13M
Average Volume (3M)790.94K
Market Cap
$1.44B
Enterprise Value$456.12M
Total Cash (Recent Filing)$996.01M
Total Debt (Recent Filing)$22.19M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Nov 11, 2025EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding60,093,933
10 Day Avg. Volume525,916
30 Day Avg. Volume790,936
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue-56.50
Enterprise Value/Gross Profit-44.85
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$77.77Price Target Upside224.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesThe JANX007 treatment has shown promising early activity results in metastatic cancer, suggesting it could significantly prolong overall survival compared to other drug mechanisms.
Innovative TreatmentsAnalyst recommends a Buy rating for Janux Therapeutics due to its potential to create significant shareholder value with innovative immunotherapy treatments.
Bears Say
Data UncertaintyUncertainty regarding the nature and details of the 2H Ph 1 data disclosures somewhat tempers expectations for the catalyst.
Financial PerformanceThe company reported no revenues for 2Q25, which aligns with consensus expectations, but a net loss of $0.55 per share, exceeding the consensus estimated net loss of $0.47 per share.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics, Inc.’s price range in the past 12 months?
Janux Therapeutics, Inc. lowest stock price was $21.97 and its highest was $71.71 in the past 12 months.
What is Janux Therapeutics, Inc.’s market cap?
Janux Therapeutics, Inc.’s market cap is $1.44B.
When is Janux Therapeutics, Inc.’s upcoming earnings report date?
Janux Therapeutics, Inc.’s upcoming earnings report date is Nov 11, 2025 which is in 63 days.
How were Janux Therapeutics, Inc.’s earnings last quarter?
Janux Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.472 by -$0.078.
Is Janux Therapeutics, Inc. overvalued?
According to Wall Street analysts Janux Therapeutics, Inc.’s price is currently Undervalued.
Does Janux Therapeutics, Inc. pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
What is Janux Therapeutics, Inc.’s EPS estimate?
Janux Therapeutics, Inc.’s EPS estimate is -0.62.
How many shares outstanding does Janux Therapeutics, Inc. have?
Janux Therapeutics, Inc. has 60,093,933 shares outstanding.
What happened to Janux Therapeutics, Inc.’s price movement after its last earnings report?
Janux Therapeutics, Inc. reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.472. Following the earnings report the stock price went up 1.107%.
Which hedge fund is a major shareholder of Janux Therapeutics, Inc.?
Currently, no hedge funds are holding shares in JANX
Janux Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.77 (224.31% Upside)
$77.77 (224.31% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 890.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.13%
12-Months-Change
Fundamentals
Return on Equity
-12.82%
Trailing 12-Months
Asset Growth
49.29%
Trailing 12-Months
Company Description
Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$77.77
▲(224.31% Upside)
Technical Analysis
Agios Pharma
―
Beam Therapeutics
―
Disc Medicine
―
Kymera Therapeutics
―
Recursion Pharmaceuticals
―
Ownership Overview
48.35% Insiders
21.43% Mutual Funds
0.10% Other Institutional Investors
20.92% Public Companies and
Individual Investors